Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pars Planitis Treatment Market Grown from 2024 to 2025?

In the past few years, the market size for pars planitis treatments has seen remarkable growth. The estimates indicate a rise from $632.88 billion in 2024 to $683.54 billion in 2025, marking an 8.0% compound annual growth rate (CAGR). A surge in understanding of autoimmune eye conditions, an increased occurrence of uveitis in children, accessible ophthalmic care, broader usage of immunosuppressants, and an increased awareness among patients for early interventions have all contributed to this growth during the historic period.

What Growth Rate Is Anticipated for the Pars Planitis Treatment Market in the Coming Years?

In the upcoming years, the market size for the treatment of pars planitis is projected to witness substantial growth, rising to $920.48 billion by 2029 with a compound annual growth rate (CAGR) of 7.7%. Factors credited for this growth during the forecast period include the increased use of biologic treatments, a rise in autoimmune diseases, enhanced interest in pediatrics eye care, wider-reaching health insurance, and a surge in demand for individualized treatments. Key trends predicted for this forecast period encompass a move towards steroid-sparing treatments, the assimilation of teleophthalmology, the manufacturing of long-acting implants, biosimilars usage in therapy, and an increase in combination treatment.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp

Who Are the Leading Companies in the Pars Planitis Treatment Market?

Major companies operating in the pars planitis treatment market are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc., Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Quantum Cryogenics Ltd., Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd., Hologic Inc., Aurobindo Pharma Limited, Santen Pharmaceutical Co. Ltd., CooperSurgical Inc., AtriCure Inc., Alimera Sciences Inc., Clearside Biomedical Inc.

What Are the Key Drivers of the Pars Planitis Treatment Market?

The escalating occurrence of pars planitis is anticipated to boost the progress of the pars planitis treatment market. Essentially an unexplained form of intermediate uveitis, pars planitis is an eye condition that primarily induces vitreous and peripheral retina inflammation, typically impacting individuals aged between 15 to 40. The growth in the number of pars planitis cases can be attributed to heightened awareness and refined diagnostic abilities due to the availability of advanced imaging tools for better and early detection. Treatments for pars planitis focus on mitigating ocular inflammation, making them indispensable for preserving eyesight and warding off complications, which ultimately lead to improved patient care. Purveying targeted treatments like corticosteroids and immunosuppressants enhances long-term ocular health and life quality. As per a case report published by the Mega Journal of Case Reports, a renowned US medical journal, in February 2025, intermediate uveitis has an occurrence rate of 1.4 to 2 per 100,000 individuals, with pars planitis, the idiopathic form, constituting 70% of these cases. Consequently, the rising incidence of pars planitis is a key element fuelling the growth of the pars planitis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24649&type=smp

What Are the Key Market Segments in the Pars Planitis Treatment Industry?

The pars planitis treatment market covered in this report is segmented –

1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments

2) By Diagnosis: Blood Tests, X-ray, Magnetic Resonance Imaging (MRI), Other Diagnosis

3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids

2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery

4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy

5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents

6) By Other Treatments: Antibiotics, Antivirals, Laser therapy

What Are the Latest Trends in the Pars Planitis Treatment Market?

Main businesses in the pars planitis treatment market are shifting their focus towards creating ground-breaking solutions like bispecific antibodies to boost immune modulation, diminish ocular inflammation, and limit systemic side effects. These proteins are specially engineered to interact with two unique antigens or targets at the same time, providing a treatment strategy that is not only more accurate but also results in less side effects. For instance, in October 2023, Genentech Inc., a biotechnology firm based in the United States, earned FDA approval for Vabysmo (faricimab-svoa), a treatment for retinal vein occlusion (RVO), as well as age-related macular degeneration and diabetic macular edema. Vabysmo, the pioneering bispecific antibody for ocular use, simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) offering a solution for inflammation and vascular leakage. This inventive approach is currently under consideration for usage in intermediate uveitis, including pars planitis, where constant inflammation in the retinal periphery necessitates durable and targeted intervention.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report

What Are the Key Regional Markets in the Pars Planitis Treatment Industry?

North America was the largest region in the pars planitis treatment market in 2024. The regions covered in the pars planitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24649

This Report Delivers Insight On:

1. How big is the pars planitis treatment market, and how is it changing globally?

2. Who are the major companies in the pars planitis treatment market, and how are they performing?

3. What are the key opportunities and risks in the pars planitis treatment market right now?

4. Which products or customer segments are growing the most in the pars planitis treatment market?

5. What factors are helping or slowing down the growth of the pars planitis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model